Company Profile

Prothena Stock Price, News & Catalysts

Ticker:
PRTA
Exchange:
NASDAQ
Sector:
Biopharma
Location:
Ireland

Stock performance

8.40 USD (+0.60%)

Close

Last updated: November 19, 2026

481M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, PRTA closed up 0.60% at $8.40. No new same-company headline was identified in the current news window.

Company overview

Protein-Dysregulation Biotechnology Company

Prothena develops therapies for neurodegenerative and rare peripheral amyloid diseases driven by misfolded or accumulated proteins. Its research focuses on antibodies and targeted biologics that remove pathogenic protein species or interfere with disease-associated aggregation.

Parkinson's Disease Collaboration

Prasinezumab is an alpha-synuclein antibody being developed with Roche for early Parkinson's disease. The program is intended to slow disease progression by targeting a pathogenic form of alpha-synuclein and has advanced into the large Phase 3 PARAISO trial.

Amyloid and Tau Programs

Coramitug, acquired by Novo Nordisk, is designed to deplete non-native transthyretin in ATTR cardiomyopathy. Moponetug, partnered with Bristol Myers Squibb, targets a disease-relevant region of tau for early Alzheimer's disease, giving Prothena exposure to two major protein-aggregation disorders through externally funded development.

CYTOPE Technology

The CYTOPE platform combines disease-selective binding with cell-internalizing capabilities to reach intracellular pathological proteins. Prothena is applying the technology to targets including TDP-43 in amyotrophic lateral sclerosis and other neurodegenerative diseases.

Partner-Funded Business Model

Much of Prothena's clinical pipeline is developed by Roche, Novo Nordisk, and Bristol Myers Squibb. This model reduces direct late-stage spending while preserving potential milestone payments and royalties, with wholly owned research focused on new protein targets and platform programs.

Future catalysts

  • Bristol Myers Squibb decision on advancement of PRX019 by year-end 2026.
  • Primary completion of the Phase 2 TargetTau-1 trial of moponetug in early Alzheimer's disease in the first half of 2027.
  • Primary completion of the coramitug PET/CT biodistribution and amyloid-depletion study in 2027.
  • Primary completion of the Phase 3 PARAISO trial of prasinezumab in early Parkinson's disease in 2029.
  • Primary completion of the Phase 3 CLEOPATTRA trial of coramitug in ATTR cardiomyopathy in 2029.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Prothena (PRTA)?

Prothena (PRTA) most recently closed at 8.40 USD, a +0.60% move versus the previous session.

What is the market cap of Prothena (PRTA)?

Prothena currently has a market capitalization of 481M USD on BioPharmSignal.

What does Prothena do?

Protein-Dysregulation Biotechnology Company Prothena develops therapies for neurodegenerative and rare peripheral amyloid diseases driven by misfolded or accumulated proteins. Its research focuses on antibodies and targeted biologics that remove pathogenic protein species or interfere with disease-associated aggregation. Parkinson's Disease...

On which exchange is PRTA stock listed?

Prothena (PRTA) is associated with NASDAQ, Ireland, Biopharma.

What is TDP-43?

Prothena is applying the technology to targets including TDP-43 in amyotrophic lateral sclerosis and other neurodegenerative diseases.

Which conditions is Prothena targeting with TDP-43?

Protein-Dysregulation Biotechnology Company Prothena develops therapies for neurodegenerative and rare peripheral amyloid diseases driven by misfolded or accumulated proteins. Its research focuses on antibodies and targeted biologics that remove pathogenic protein species or interfere with disease-associated aggregation. Parkinson's Disease...

How does Prothena describe recent progress with TDP-43?

Bristol Myers Squibb decision on advancement of PRX019 by year-end 2026. Primary completion of the Phase 2 TargetTau-1 trial of moponetug in early Alzheimer's disease in the first half of 2027. Primary completion of the coramitug PET/CT biodistribution and amyloid-depletion study in 2027. Primary completion of the Phase 3 PARAISO trial of prasinezumab in...

What is prasinezumab?

Parkinson's Disease Collaboration Prasinezumab is an alpha-synuclein antibody being developed with Roche for early Parkinson's disease.